FY2019 EPS Estimates for Catabasis Pharmaceuticals, Inc. (CATB) Cut by Analyst

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) – Investment analysts at Wedbush reduced their FY2019 earnings estimates for Catabasis Pharmaceuticals in a research report issued to clients and investors on Wednesday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will earn ($1.89) per share for the year, down from their previous forecast of ($1.79). Wedbush has a “Outperform” rating and a $4.00 price target on the stock. Wedbush also issued estimates for Catabasis Pharmaceuticals’ FY2020 earnings at ($2.39) EPS and FY2021 earnings at ($1.39) EPS.

Other analysts have also recently issued reports about the company. Citigroup Inc. set a $3.50 price objective on Catabasis Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday. Oppenheimer Holdings, Inc. increased their price objective on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research report on Thursday. CIBC reaffirmed an “outperform” rating and set a $7.00 price objective (up from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday. HC Wainwright increased their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Cowen and Company reaffirmed a “market perform” rating and set a $2.00 price objective on shares of Catabasis Pharmaceuticals in a research report on Friday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $5.42.

WARNING: This article was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://ledgergazette.com/2017/10/09/fy2019-eps-estimates-for-catabasis-pharmaceuticals-inc-catb-cut-by-analyst.html.

Catabasis Pharmaceuticals (CATB) opened at 2.49 on Monday. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $5.51. The company’s market cap is $55.98 million. The company has a 50-day moving average of $2.00 and a 200-day moving average of $2.00.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.08.

Institutional investors and hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $144,000. Renaissance Technologies LLC acquired a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $106,000. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at approximately $271,000. 32.90% of the stock is owned by institutional investors and hedge funds.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platfor

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) – Investment analysts at Wedbush reduced their FY2019 earnings estimates for Catabasis Pharmaceuticals in a research report issued to clients and investors on Wednesday. Wedbush analyst L. Moussatos now forecasts that the biotechnology company will earn ($1.89) per share for the year, down from their previous forecast of ($1.79). Wedbush has a “Outperform” rating and a $4.00 price target on the stock. Wedbush also issued estimates for Catabasis Pharmaceuticals’ FY2020 earnings at ($2.39) EPS and FY2021 earnings at ($1.39) EPS.

Other analysts have also recently issued reports about the company. Citigroup Inc. set a $3.50 price objective on Catabasis Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday. Oppenheimer Holdings, Inc. increased their price objective on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research report on Thursday. CIBC reaffirmed an “outperform” rating and set a $7.00 price objective (up from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday. HC Wainwright increased their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, Cowen and Company reaffirmed a “market perform” rating and set a $2.00 price objective on shares of Catabasis Pharmaceuticals in a research report on Friday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $5.42.

WARNING: This article was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://ledgergazette.com/2017/10/09/fy2019-eps-estimates-for-catabasis-pharmaceuticals-inc-catb-cut-by-analyst.html.

Catabasis Pharmaceuticals (CATB) opened at 2.49 on Monday. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $5.51. The company’s market cap is $55.98 million. The company has a 50-day moving average of $2.00 and a 200-day moving average of $2.00.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.08.

Institutional investors and hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $144,000. Renaissance Technologies LLC acquired a new stake in shares of Catabasis Pharmaceuticals in the 1st quarter valued at approximately $106,000. Finally, Virtu KCG Holdings LLC acquired a new stake in shares of Catabasis Pharmaceuticals in the 2nd quarter valued at approximately $271,000. 32.90% of the stock is owned by institutional investors and hedge funds.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Earnings History and Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply